Clinical Trials
7
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- ReGenTree, LLC
- Target Recruit Count
- 70
- Registration Number
- NCT05555589
- Locations
- 🇺🇸
Harvard Eye Associates, Laguna Hills, California, United States
🇺🇸Loma Linda University Eye Institute, Loma Linda, California, United States
🇺🇸Nvision Clinical Research, LLC., Los Angeles, California, United States
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3
- First Posted Date
- 2019-05-06
- Last Posted Date
- 2022-05-09
- Lead Sponsor
- ReGenTree, LLC
- Target Recruit Count
- 700
- Registration Number
- NCT03937882
- Locations
- 🇺🇸
Cornea and Cataract Consultants of Arizona, Phoenix, Arizona, United States
🇺🇸Eye Research Foundation, Newport Beach, California, United States
🇺🇸Vision Institute, Colorado Springs, Colorado, United States
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2
- First Posted Date
- 2016-11-29
- Last Posted Date
- 2022-01-05
- Lead Sponsor
- ReGenTree, LLC
- Target Recruit Count
- 601
- Registration Number
- NCT02974907
- Locations
- 🇺🇸
Andover, MA, Andover, Massachusetts, United States
Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1
- First Posted Date
- 2015-11-09
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- ReGenTree, LLC
- Target Recruit Count
- 18
- Registration Number
- NCT02600429
- Locations
- 🇺🇸
Hull Eye Center, Lancaster, California, United States
🇺🇸Vision Institute, Colorado Springs, Colorado, United States
🇺🇸Eye Center of Northern Colorado, Fort Collins, Colorado, United States
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1
- First Posted Date
- 2015-11-05
- Last Posted Date
- 2019-10-17
- Lead Sponsor
- ReGenTree, LLC
- Target Recruit Count
- 317
- Registration Number
- NCT02597803
- Locations
- 🇺🇸
Andover, MA, Andover, Massachusetts, United States
- Prev
- 1
- 2
- Next